Data Highlight Medtronic Vascular Innovations at Charing Cross 2017
(Thomson Reuters ONE) -
New Data from the Global ENGAGE Registry, IN.PACT Admiral Global Study, and
VeClose Study Among Key Presentations
LONDON and DUBLIN - April 20, 2017 - Medtronic plc (NYSE: MDT) today announced
key clinical studies for its leading vascular interventional portfolio will be
featured at the annual 2017 Charing Cross Symposium (CX), one of the world's
largest educational meetings specializing in vascular and endovascular disease
management, in London from April 25-28, 2017. This year, more than 40
presentations, cases and hands-on demonstration sessions will highlight
Medtronic aortic, endoVenous, and peripheral devices.
The highly anticipated five-year durability data from the global ENGAGE Registry
will be presented on Wednesday, April 26, 2017. Philippe Cuypers, M.D., of
Catharina Hospital in Eindhoven, The Netherlands will report on the long-term
performance of the Endurant® stent graft system in patients with abdominal
aortic aneurysms (AAA).
Peter Holt, M.D., from St George's University of London will present on a new
analysis that will utilize data from the ENGAGE Registry to inform clinicians'
treatment decisions following endovascular aneurysm repair (EVAR). In two
separate sessions, Prof. Hence Verhagen, M.D., Ph.D., of University Medical
Center in Rotterdam, The Netherlands and Ross Milner, M.D., of University of
Chicago will present on sub-analyses of complex patients(1) from the ENGAGE
Registry.
New sub-analyses from the IN.PACT Global Study will be unveiled in two "Podium
First" presentations on Tuesday, April 25, 2017 focusing on real-world patient
outcomes, including the durability, safety, and efficacy of the IN.PACT(TM)
Admiral(TM) drug-coated balloon (DCB) to treat challenging and complex lesions
in patients with peripheral artery disease. Gary Ansel, M.D., of OhioHealth
Riverside Methodist Hospital in Columbus, Ohio, will present one-year results
comparing standard IDE-like patients versus complex (wider criteria) patient
cohorts.
Shortly following, Fabrizio Fanelli, M.D., EBIR, of Sapienza University of Rome,
Italy will share findings from a subset analysis on the impact of calcification
when patients with complete total occlusions and long lesions are treated with
the IN.PACT Admiral DCB.
The VenaSeal(TM) closure system will be featured in two key clinical
presentations, including the three-year results of Medtronic's pivotal VeClose
study and 12-month results from the WAVES study, which is an independent,
physician-sponsored study. Both data sets will be presented by Kathleen Gibson,
M.D., of Lake Washington Vascular in Seattle on Tuesday, April 25, 2017.
VenaSeal is a non-tumescent, non-thermal, and non-sclerosant procedure that uses
a proprietary medical adhesive to close superficial veins of the lower
extremities, such as the great saphenous vein (GSV), in patients with venous
reflux.
"With clinical trials and registries that lead the industry in rigor and
comprehensiveness, Medtronic is helping to create standards of care that
underpin durable, consistent, and safe vascular procedures," said Tony Semedo,
president and senior vice president of Medtronic's Aortic & Peripheral Vascular
division. "We look forward to unveiling the latest clinical evidence across our
interventional therapies at Charing Cross."
A schedule of selected Medtronic presentations appears below in chronological
order in Greenwich Mean Time.
Tuesday, April 25, 2017
* Drug-Coated Balloon Consensus Update (Upper Main Auditorium)
* 10:30 a.m.: Podium First: 12-month outcomes of standard vs. wider usage
of DCB - IN.PACT global study; Gary Ansel, M.D.
* 10:52 a.m.: Podium First: Outcomes of DCB with calcification, >15 cm,
complete total occlusion and TASC C and D lesions - IN.PACT study;
Fabrizio Fanelli, M.D.
* Aortic Edited Cases, Thoracic (Pillar Hall Learning Centre)
* 11:00 a.m.: The new Valiant Navion device; Ali Azizzadeh, M.D.
* Varicose Vein Management - INTERVENTION METHOD and Outcomes (Lower Main
Auditorium)
* 2:19 p.m.: Endovenous adhesive vs. radiofrequency ablation at three
years - VeClose study; Kathleen Gibson, M.D.
* 3:12 p.m.: Endovenous adhesive occlusion for advanced superficial venous
disease - WAVES study data at 12 months; Kathleen Gibson, M.D.
* Aortic Edited Cases, Abdominal (Pillar Hall Learning Centre)
* 4:00 p.m.: Technique for endoanchor in the primary and secondary
situations; Jean-Paul de Vries, M.D.
Wednesday, April 26, 2017
* Venous Edited Cases (Venous City - Exhibition Level)
* 9:45 a.m.: Performing cyanoacrylate closure (VenaSeal) of a great
saphenous vein; Sudip Ray, M.D.
* Peripheral Edited Cases (Lower Main Auditorium)
* 10:30 a.m.: IN.PACT drug-coated balloon in the treatment of AV fistula -
evidence, tips and tricks; Andrew Holden, M.D.
* INTERVENTION METHOD (Upper Main Auditorium)
* 10:38 a.m.: Risk and clinical surveillance of EVAR - Long-term
Estimation of Aortic Risk (LEAR); Peter Holt, M.D.
* 10:46 a.m.: Safety considerations with hostile neck 10-15mm; Hence
Verhagen, M.D.(1)
* Peripheral Edited and Live Cases (Lower Main Auditorium)
* 11:30 a.m.: The value of DCB in the popliteal artery; Koen Deloose, M.D.
* 12:00 p.m.: Combination therapy: directional atherectomy with HawkOne
6F followed by IN.PACT drug-coated balloon for the treatment of
femoropopliteal lesions; Theodosias Bisdas, M.D. & Arne Schwindt, M.D.
* Outcomes and Follow-Up (Upper Main Auditorium)
* 12:14 p.m.: ENGAGE registry - five-year durability data; Philippe
Cuypers, M.D.
* Strategies, devices and techniques to optimise outcomes for endovascular
treatment of complex AAAs (Upper Main Auditorium)
* 12:33 p.m.: Endoanchor in the short neck(1); William Jordan, M.D.
* 12:42 p.m.: Optimising the outcomes of chEVAR through a standardisation
of patient selection, devices and technique; Konstantions Donas, M.D.
* Venous Hands-On Workshop (Venous City - Exhibition Level)
* 9:30 a.m.: ClosureFast; Tristan Lane, M.D. & Ravinder Singh-Ranger, M.D.
* 9:30 a.m.: VenaSeal; Kathleen Gibson, M.D. & Supid Ray, M.D.
Thursday, April 27, 2017
* Whether to Intervene (Lower Main Auditorium)
* 8:52 a.m.: A new classification system for femoropopliteal artery
patterns of restenosis; Lawrence Garcia, M.D.
* INTERVENTION METHOD and Outcomes (Upper Main Auditorium)
* 2:14 p.m.: Rationale for supra vs. infrarenal choice(1); Ross Milner,
M.D.
* Venous Hands-On Workshop (Venous City - Exhibition Level)
* 9:30 a.m.: Abre Stent; Erin Murphy, M.D.
In collaboration with leading clinicians, researchers, and scientists worldwide,
Medtronic offers the broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services of the highest
quality that deliver clinical and economic value to healthcare consumers and
providers around the world.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among
the world's largest medical technology, services and solutions companies -
alleviating pain, restoring health and extending life for millions of people
around the world. Medtronic employs more than 88,000 people worldwide, serving
physicians, hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from anticipated
results.
-end-
(1) In the U.S., the Endurant II/IIs stent system is approved for neck lengths
/>= 10 mm and <= 60° infra-renal angulation.
Contacts:
Krystin Hayward Leong
Public Relations
+1-508-261-6512
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medtronic plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2017 - 15:00 Uhr
Sprache: Deutsch
News-ID 537364
Anzahl Zeichen: 9646
contact information:
Town:
Dublin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 301 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Data Highlight Medtronic Vascular Innovations at Charing Cross 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Medtronic plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
